Dr. Paul Harmatz, MD

Pediatric Gastroenterology Oakland, CA Male
NPI: 1255435301
Total Payments
$284,836
2024 Payments
$40,369
Companies
8
Transactions
275

Payment Breakdown by Category

Consulting$92,158 (32.4%)
Travel$68,820 (24.2%)
Education$68,500 (24.0%)
Other$42,129 (14.8%)
Research$7,719 (2.7%)
Food & Beverage$5,511 (1.9%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $92,158 27 32.4%
Travel and Lodging $68,820 86 24.2%
Education $68,500 73 24.0%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $41,274 7 14.5%
Unspecified $7,719 7 2.7%
Food and Beverage $5,511 74 1.9%
Grant $854.39 1 0.3%

Payments by Type

General
$277,117
268 transactions
Research
$7,719
7 transactions

Top Paying Companies

Company Total Records Latest Year
BioMarin Pharmaceutical Inc. $199,686 182 $0 (2024)
Shire North American Group Inc $41,312 66 $0 (2019)
Chiesi USA, Inc. $22,682 8 $0 (2022)
GENZYME CORPORATION $17,632 10 $0 (2024)
Alexion Pharmaceuticals, Inc. $1,500 1 $0 (2017)
Takeda Pharmaceuticals U.S.A., Inc. $1,473 6 $0 (2023)
PFIZER INC. $461.77 1 $0 (2017)
Sobi, Inc $89.40 1 $0 (2019)

Payment History by Year

Year Amount Transactions Top Company
2024 $40,369 16 BioMarin Pharmaceutical Inc. ($26,705)
2023 $2,834 9 Takeda Pharmaceuticals U.S.A., Inc. ($1,416)
2022 $6,128 3 Chiesi USA, Inc. ($6,128)
2021 $10,200 1 Chiesi USA, Inc. ($10,200)
2020 $4,532 4 BioMarin Pharmaceutical Inc. ($4,475)
2019 $15,041 20 BioMarin Pharmaceutical Inc. ($7,167)
2018 $133,088 156 BioMarin Pharmaceutical Inc. ($124,626)
2017 $72,645 66 BioMarin Pharmaceutical Inc. ($36,177)

All Payment Transactions

275 individual payment records from CMS Open Payments — Page 1 of 11

Date Company Product Nature Form Amount Type
12/31/2024 BioMarin Pharmaceutical Inc. — Consulting Fee Cash or cash equivalent $2,967.18 General
12/31/2024 BioMarin Pharmaceutical Inc. — Consulting Fee Cash or cash equivalent $2,967.18 General
12/31/2024 BioMarin Pharmaceutical Inc. — Consulting Fee Cash or cash equivalent $2,967.18 General
12/31/2024 BioMarin Pharmaceutical Inc. — Consulting Fee Cash or cash equivalent $2,967.18 General
12/31/2024 BioMarin Pharmaceutical Inc. — Consulting Fee Cash or cash equivalent $2,967.18 General
12/31/2024 BioMarin Pharmaceutical Inc. — Consulting Fee Cash or cash equivalent $2,967.18 General
12/31/2024 BioMarin Pharmaceutical Inc. — Consulting Fee Cash or cash equivalent $2,967.18 General
12/31/2024 BioMarin Pharmaceutical Inc. — Consulting Fee Cash or cash equivalent $2,967.18 General
12/31/2024 BioMarin Pharmaceutical Inc. — Consulting Fee Cash or cash equivalent $2,967.18 General
11/14/2024 GENZYME CORPORATION — Consulting Fee Cash or cash equivalent $12,012.00 General
11/14/2024 GENZYME CORPORATION — Travel and Lodging In-kind items and services $616.14 General
11/14/2024 GENZYME CORPORATION — Travel and Lodging In-kind items and services $301.39 General
11/14/2024 GENZYME CORPORATION — Food and Beverage In-kind items and services $259.83 General
11/14/2024 GENZYME CORPORATION — Travel and Lodging In-kind items and services $236.16 General
11/14/2024 GENZYME CORPORATION — Travel and Lodging Cash or cash equivalent $120.00 General
11/07/2024 GENZYME CORPORATION CEREZYME (Biological), CERDELGA Food and Beverage In-kind items and services $119.27 General
Category: Genetic Disease
12/31/2023 BioMarin Pharmaceutical Inc. — Consulting Fee Cash or cash equivalent $491.78 General
10/16/2023 GENZYME CORPORATION — Grant Cash or cash equivalent $854.39 General
04/27/2023 Takeda Pharmaceuticals U.S.A., Inc. — — In-kind items and services $486.80 Research
Study: A Phase 3, Open-label, Non-controlled, Multi-dose, Extension Study to Evaluate the Long-term Safety and Tolerability of IGSC, 20% in Japanese Subjects With Primary Immunodeficiency Disease (PID)
04/27/2023 Takeda Pharmaceuticals U.S.A., Inc. — — In-kind items and services $336.59 Research
Study: A Phase 3, Open-label, Non-controlled, Multi-dose, Extension Study to Evaluate the Long-term Safety and Tolerability of IGSC, 20% in Japanese Subjects With Primary Immunodeficiency Disease (PID)
04/27/2023 Takeda Pharmaceuticals U.S.A., Inc. — — In-kind items and services $250.00 Research
Study: A Phase 3, Open-label, Non-controlled, Multi-dose, Extension Study to Evaluate the Long-term Safety and Tolerability of IGSC, 20% in Japanese Subjects With Primary Immunodeficiency Disease (PID)
04/27/2023 Takeda Pharmaceuticals U.S.A., Inc. — — In-kind items and services $234.62 Research
Study: A Phase 3, Open-label, Non-controlled, Multi-dose, Extension Study to Evaluate the Long-term Safety and Tolerability of IGSC, 20% in Japanese Subjects With Primary Immunodeficiency Disease (PID)
04/27/2023 Takeda Pharmaceuticals U.S.A., Inc. — — In-kind items and services $107.96 Research
Study: A Phase 3, Open-label, Non-controlled, Multi-dose, Extension Study to Evaluate the Long-term Safety and Tolerability of IGSC, 20% in Japanese Subjects With Primary Immunodeficiency Disease (PID)
02/25/2023 GENZYME CORPORATION ENJAYMO (Biological) Food and Beverage In-kind items and services $27.07 General
Category: Hematology
02/22/2023 BioMarin Pharmaceutical Inc. Vimizim (Biological) Food and Beverage In-kind items and services $44.40 General
Category: MPS IVA
123…11»

Research Studies & Clinical Trials

Study Name Company Amount Records
NONE Chiesi USA, Inc. $6,303 2
A Phase 3, Open-label, Non-controlled, Multi-dose, Extension Study to Evaluate the Long-term Safety and Tolerability of IGSC, 20% in Japanese Subjects With Primary Immunodeficiency Disease (PID) Takeda Pharmaceuticals U.S.A., Inc. $1,416 5

About Dr. Paul Harmatz, MD

Dr. Paul Harmatz, MD is a Pediatric Gastroenterology healthcare provider based in Oakland, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255435301.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paul Harmatz, MD has received a total of $284,836 in payments from pharmaceutical and medical device companies, with $40,369 received in 2024. These payments were reported across 275 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($92,158).

Practice Information

  • Specialty Pediatric Gastroenterology
  • Location Oakland, CA
  • Active Since 09/11/2006
  • Last Updated 07/08/2007
  • Taxonomy Code 2080P0206X
  • Entity Type Individual
  • NPI Number 1255435301

Products in Payments

  • Vimizim (Biological) $126,399
  • Naglazyme (Biological) $40,110
  • ELAPRASE (Biological) $19,898
  • ELAPRASE (Drug) $9,050
  • BMN 111 (Biological) $4,782
  • ALDURAZYME (Drug) $3,086
  • Strensiq (Drug) $1,500
  • Palynziq (Drug) $224.63
  • BMN 165 (Drug) $126.75
  • CEREZYME (Biological) $119.27
  • Brineura (Biological) $76.16
  • ENJAYMO (Biological) $27.07
  • VPRIV (Biological) $13.36

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Pediatric Gastroenterology Doctors in Oakland

Dr. Joanna Yeh, Md, MD

Pediatric Gastroenterology — Payments: $1,389

Pediatric Gastroenterology $1,389

Dr. Arathi Lakhole, M.d, M.p.h, M.D, M.P.H

Pediatric Gastroenterology — Payments: $7.57

Pediatric Gastroenterology $7.57

Mala Setty, M.d, M.D

Pediatric Gastroenterology — Payments: $5.12

Pediatric Gastroenterology $5.12

Prita Mohanty, Md, MD

Pediatric Gastroenterology — Payments: $0.78

Pediatric Gastroenterology $0.78

Edward Rich, Md, MD

Pediatric Gastroenterology

Pediatric Gastroenterology